Rheumatoid arthritis and bone health

Ashai, Shanze; Harvey, Nicholas C.

doi:10.7861/clinmed.20.6.rabh

Cited by 11 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several signaling molecules, including cytokines, receptors, and transcription factors, are shared between the skeletal and immune system ( Okamoto and Takayanagi, 2019 ). Also, many auto-immune and inflammatory disorders are characterized by bone destruction, including RA and Crohn’s disease ( Veauthier and Hornecker, 2018 ; Madel et al, 2019 ; Ashai and Harvey, 2020 ). At last, a spectrum of bone alterations has been described in several genetically defined autoimmune conditions, caused by mutations in innate immune components ( Bader-Meunier et al, 2018 ).…”

Section: Osteoclast Phenotype Functions and Biological Activitiesmentioning

confidence: 99%

Multinucleated Giant Cells: Current Insights in Phenotype, Biological Activities, and Mechanism of Formation

Ahmadzadeh

Vanoppen

Rosé

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Monocytes and macrophages are innate immune cells with diverse functions ranging from phagocytosis of microorganisms to forming a bridge with the adaptive immune system. A lesser-known attribute of macrophages is their ability to fuse with each other to form multinucleated giant cells. Based on their morphology and functional characteristics, there are in general three types of multinucleated giant cells including osteoclasts, foreign body giant cells and Langhans giant cells. Osteoclasts are bone resorbing cells and under physiological conditions they participate in bone remodeling. However, under pathological conditions such as rheumatoid arthritis and osteoporosis, osteoclasts are responsible for bone destruction and bone loss. Foreign body giant cells and Langhans giant cells appear only under pathological conditions. While foreign body giant cells are found in immune reactions against foreign material, including implants, Langhans giant cells are associated with granulomas in infectious and non-infectious diseases. The functionality and fusion mechanism of osteoclasts are being elucidated, however, our knowledge on the functions of foreign body giant cells and Langhans giant cells is limited. In this review, we describe and compare the phenotypic aspects, biological and functional activities of the three types of multinucleated giant cells. Furthermore, we provide an overview of the multinucleation process and highlight key molecules in the different phases of macrophage fusion.

show abstract

Section: Osteoclast Phenotype Functions and Biological Activitiesmentioning

confidence: 99%

Multinucleated Giant Cells: Current Insights in Phenotype, Biological Activities, and Mechanism of Formation

Ahmadzadeh

Vanoppen

Rosé

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…RA is highly associated with OSP, affecting as many as 50% of all patients, with the risk for men and premenopausal women being double that of those without RA in age matched controls. 82 Periarticular osteopenia, a decrease in both cortical and trabecular bone, increased cortical porosity and lower volumetric bone mineral density (BMD) are all hallmarks of RA ( Figure 3 ). 83 The mechanisms for this are many such as contributions by TNF-α and IL-6 release indirectly leading to receptor activation of nuclear factor kappa-B ligand (RANKL) activation which in turn activates osteoclast formation and activation while simultaneously decreasing osteoblastogenesis.…”

Section: Introductionmentioning

confidence: 99%

Cardiovascular disease and bone health in aging female rheumatic disease populations: A review

Cabling

Sandhu

Downey

et al. 2023

Womens Health (Lond Engl)

View full text Add to dashboard Cite

Rheumatic diseases cover a wide spectrum of conditions, including primary and secondary degenerative joint diseases and autoimmune inflammatory rheumatic diseases. The risks of cardiovascular disease and osteoporosis and resultant fractures in aging female rheumatic disease populations, especially those with autoimmune rheumatic diseases, are increased. Changes in the immune system in aging populations need to be considered especially among patients with autoimmune rheumatic diseases. Immunosenescence is closely aligned to reduced adaptive immunity and increased non-specific innate immunity leading to chronic inflammation of inflammaging. The effective use of disease-modifying antirheumatic drugs to control autoimmune rheumatic diseases may also mitigate factors leading to cardiovascular disease and osteoporosis. Rheumatic diseases, which largely manifest as arthritis, predispose patients to premature joint degeneration and poor bone health and therefore have a higher risk of developing end-stage arthritis requiring joint arthroplasties sooner or more often than other patients without rheumatic disease.

show abstract

“… 1 , 2 , 3 , 4 Moreover, the immune mediate inflammation might further erode articular bone and lead to joint deformity, bone destruction, and disability. 1 , 2 , 3 , 4 , 5 In addition to severe symptoms described above, excess comorbidities (including fragility fracture, osteoarthritis, etc) are also along with RA patients, which could reduce their quality of life. 6 , 7 Aiming to control symptoms and progression of RA, many treatments have been applied, which mainly include nonsteroidal anti‐inflammatory drug (NSAID), conventional synthetic disease‐modifying antirheumatic drugs (cDMARDs), glucocorticoids (GC), biologic DMARDs, etc.…”

Section: Introductionmentioning

confidence: 99%

Inter‐alpha‐trypsin inhibitor heavy chain 4: A serologic marker relating to disease risk, activity, and treatment outcomes of rheumatoid arthritis

2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Objective Inter‐alpha‐trypsin inhibitor heavy chain 4 (ITIH4) regulates immunity and inflammation, but its clinical role in rheumatoid arthritis (RA) patients remains unclear. Hence, this study was conducted to explore the association of circulating ITIH4 with disease risk, clinical features, inflammatory cytokines, and treatment outcomes of RA. Methods After the enrollment of 93 active RA patients and 50 health controls (HCs), their serum ITIH4 level was analyzed by enzyme‐linked immunosorbent assay (ELISA). For RA patients only, serum ITIH4 level at week (W) 6 and W12 after treatment was also analyzed. Besides, serum tumor necrosis factor‐alpha (TNF‐α), interleukin (IL)‐1β, IL‐6, and IL‐17A at baseline of RA patients were also detected by ELISA. Results ITIH4 was downregulated in RA patients (151.1 (interquartile range (IQR): 106.2–213.5) ng/mL) than in HCs (306.8 (IQR: 238.9–435.1) ng/mL) (p < 0.001). Furthermore, ITIH4 was negatively related to C‐reactive protein (CRP) (rs = −0.358, p < 0.001) and 28‐joint disease activity score using erythrocyte sedimentation rate (DAS28‐ESR) (rs = −0.253, p = 0.014) in RA patients, but not correlated with other clinical features (all p > 0.05). Besides, ITIH4 was negatively linked with TNF‐α (rs = −0.337, p = 0.001), IL‐6 (rs = −0.221, p = 0.033), and IL‐17A (rs = −0.368, p < 0.001) in RA patients, but not correlated with IL‐1β (rs = −0.195, p = 0.061). Moreover, ITIH4 was gradually elevated in RA patients from baseline to W12 after treatment (p < 0.001). Additionally, the increment of ITIH4 at W6 and W12 was linked with treatment response and remission in RA patients (all p < 0.05). Conclusion Circulating ITIH4 possesses clinical utility in monitoring disease risk, inflammation, disease activity, and treatment outcomes of RA.

show abstract

Rheumatoid arthritis and bone health

Cited by 11 publications

References 20 publications

Multinucleated Giant Cells: Current Insights in Phenotype, Biological Activities, and Mechanism of Formation

Multinucleated Giant Cells: Current Insights in Phenotype, Biological Activities, and Mechanism of Formation

Cardiovascular disease and bone health in aging female rheumatic disease populations: A review

Inter‐alpha‐trypsin inhibitor heavy chain 4: A serologic marker relating to disease risk, activity, and treatment outcomes of rheumatoid arthritis

Contact Info

Product

Resources

About